Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Activating mutations in fibroblast growth factor receptor-3 (FGFR3) are prevalent in bladder cancer, particularly low-grade papillary tumors.
• FGFR3 overexpression is also common in muscle-invasive bladder cancer, highlighting its role as a therapeutic target.
• Current FGFR3 inhibitors are primarily small molecule kinase inhibitors; a specific monoclonal antibody (R3Mab) offers a novel therapeutic approach.

Purpose of the Study:

• To evaluate the mutation and expression status of FGFR3 in urothelial cancer cell lines and patient cohorts.
• To assess the preclinical efficacy of R3Mab, a novel FGFR3-targeting monoclonal antibody, in bladder cancer models.
• To provide evidence for the clinical translation of FGFR3 inhibition using R3Mab.

Main Methods:

• Analysis of FGFR3 mutation and expression in 19 urothelial cancer cell lines.
• Evaluation of FGFR3 status in a cohort of 170 American bladder cancer patients.
• Testing the inhibitory activity of R3Mab in three orthotopic bladder cancer xenograft models.

Main Results:

• FGFR3 alterations (mutation/overexpression) were confirmed in the studied cell lines and patient cohort.
• R3Mab demonstrated significant inhibition of tumor growth in preclinical bladder cancer xenografts.
• R3Mab effectively suppressed corresponding cell signaling pathways in the tested models.

Conclusions:

• FGFR3 is a validated target in bladder cancer, with significant mutation and overexpression rates.
• R3Mab exhibits potent preclinical anti-tumor activity and pathway inhibition in bladder cancer.
• These findings support the clinical development of R3Mab for bladder cancer treatment.